Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:16:42.188Z.
Consensus retrieved: 2026-10-06T11:28:09.247Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:16:42.188Z.
Quote observation: 2026-10-06T19:03:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6da64a8b1a2a274dcb8686c6d20e6c80d542b1d2a14b58c5ff35188fa74041c0
Forward PE Ratio (N/A) = Dated Quote Price ($2.08) / Consensus Forward EPS ($-2.28)
FORWARD PE RATIO
N/A
Femasys Inc.
Market Cap
$6.28M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Femasys Inc. (FEMY) | $6.28M | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.66M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.90M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.88M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.72M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.77M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.08, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.28 | $-2.62 – $-2.03 | 1 | n/m |
| 2027-12-31 | $-1.75 | $-2.13 – $-1.37 | 2 | n/m |
| 2028-12-31 | $-1.22 | $-1.76 – $-0.51 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
